Archives of Toxicology

, Volume 93, Issue 10, pp 3033–3035 | Cite as

Response to Hethey et al., 2019 letter to the editor in archives of toxicology

  • Go-Wun Choi
  • Ju Hee Kim
  • Yong-Bok Lee
  • Hea-Young ChoEmail author
Letter to the Editor, News and Views

The authors are grateful to Dr. Hethey and his colleagues for their interest in our article entitled “Exploring sex differences in human health risk assessment for PFNA and PFDA using a PBPK model” and their thoughtful comments on them. While their critical comments are deeply appreciated, the authors would like to take this opportunity to write a rebuttal.

First, although Hethey et al. (2019) have pointed out that the PBPK model structure inappropriately reflected renal physiology, this comment was based on calculation errors. Second, they have mentioned that the simple allometric scaling in our PBPK model did not take into consideration of the inter-species and gender differences of kidney transporters which play a key role in the disposition of per- and poly-fluoroalkyl substances (PFASs). However, again, their conclusions were based on misinterpretation of the previous studies.

In point 1, Hethey et al. (2019) have claimed that the PBPK model structure needs to be refined to...


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Calafat AM, Kuklenyik Z, Caudill SP, Reidy JA, Needham LL (2006) Perfluorochemicals in pooled serum samples from United States residents in 2001 and 2002. Environ Sci Technol 40(7):2128–2134. CrossRefPubMedGoogle Scholar
  2. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093–1095. CrossRefPubMedGoogle Scholar
  3. Han X, Nabb DL, Russell MH, Kennedy GL, Rickard RW (2012) Renal elimination of perfluorocarboxylates (PFCAs). Chem Res Toxicol 25(1):35–46. CrossRefPubMedGoogle Scholar
  4. Harada K, Inoue K, Morikawa A, Yoshinaga T, Saito N, Koizumi A (2005) Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion. Environ Res 99(2):253–261. CrossRefPubMedGoogle Scholar
  5. Hethey C, Mielke H, Gundert-Remy U (2019) Comment on ‘Kim, S.-J., Choi, E.-J., Choi, G.-W., Lee, Y.-B., and Cho, H.-Y. (2019). Exploring sex differences in human health risk assessment for PFNA and PFDA using a PBPK model, Arch Toxicol 93:311–330’. Arch Toxicol 93(6):1769–1770. CrossRefPubMedGoogle Scholar
  6. Kudo N, Suzuki E, Katakura M, Ohmori K, Noshiro R, Kawashima Y (2001) Comparison of the elimination between perfluorinated fatty acids with different carbon chain length in rats. Chem-Biol Interact 134(2):203–216. CrossRefPubMedGoogle Scholar
  7. Loccisano AE, Campbell JL Jr, Butenhoff JL, Andersen ME, Clewell HJ 3rd (2012) Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol 33(4):452–467. CrossRefPubMedGoogle Scholar
  8. Olsen GW, Church TR, Miller JP et al (2003) Perfluorooctanesulfonate and other fluorochemicals in the serum of American red cross adult blood donors. Environ Health Perspect 111(16):1892–1901. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Olsen GW, Burris JM, Ehresman DJ et al (2007) Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115(9):1298–1305. CrossRefPubMedPubMedCentralGoogle Scholar
  10. Sabolić I, Breljak D, Ljubojević M, Brzica H (2011) Are mice, rats, and rabbits good models for physiological, pharmacological and toxicological studies in humans? Period Biol 113(1):7–16Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.College of PharmacyCHA UniversitySeongnam-siRepublic of Korea
  2. 2.College of PharmacyChonnam National UniversityGwangjuRepublic of Korea

Personalised recommendations